2.00 / AMA PRA Category 1 CreditsTM 2.00 / AANP Contact Hours
Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)
Supported by an educational grant from Novartis Pharmaceuticals Corporation
In recent years, uncontrolled asthma has been recognized to be a heterogeneous syndrome with different underlying pathophysiological features. Efforts to define key drivers for asthma “phenotypes” have focused on the role of eosinophilic inflammation and Th2 type immunological pathways, and led to the clinical development of biologics that antagonize IL-5, IL-4, and IL-13 pathways. With the availability of three biologics for asthma treatment and several other biologics in clinical development, it is imperative that all clinicians be trained on the stepwise approach to asthma treatment described in the guidelines as well as on these novel treatment options so they are able to individualize treatment and optimize patient outcomes.
During this Medical Crossfire, expert faculty will engage in a multidisciplinary roundtable discussion that includes a pulmonologist, primary care clinician, nurse practitioner and a patient advocate to discuss how to best optimize and individualize asthma management. A focus will be placed on managing the severe, uncontrolled asthma patient.
Physicians, nurses, nurse practitioners, and physician assistants
At the conclusion of this activity, participants should be better able to:
Articulate the importance of providing self-management education and asthma action plan (AAP) to asthma patients
Appropriately evaluate patients with asthma for level of control, asthma severity, and risk of exacerbations
Explore the current guidelines for asthma treatment
Differentiate between the different biologics based on mechanism of action and phenotypes
Describe how to make individualized treatment selections in patients with uncontrolled asthma that appropriately address the impact of underlying inflammation
Peter Salgo, MD Professor of Medicine and Anesthesiology Columbia University College of Physicians and Surgeons New York, NY
Dr. Salgo has no relevant financial relationships with commercial interests to disclose.
Natasha McClure, DNP, RN, CPNP Instructor Vanderbilt University School of Nursing Nashville, TN
Dr. McClure has no relevant financial relationships with commercial interests to disclose.
Michael E. Wechsler, MD Professor of Medicine Director, Asthma Program Co-Director, Cohen Family NJH Asthma Institute National Jewish Health Denver, CO
Dr. Wechsler has the following relevant financial relationships with commercial interest to disclose: Grant/Research Support: Sanofi/Regeneron Consultant: AstraZeneca, Teva, Boston Scientific, Boehringer Ingelheim, Genentech, Viatris, and Gliacure
Mark Titus Patient Advocate Clinton Township, MI
Mr. Titus has no relevant financial relationships with commercial interests to disclose.
Accredited Provider Disclosure
Kristen Delisi, NP, Lindsay Borvansky, Andrea Funk, and Laura Gilsdorf have no relevant financial relationships with commercial interests to disclose
Publishing Staff Disclosures
Physicians' Education Resource®, LLC (PER®) Planning Staff: Dave Heckard, Maryjo Dixon, RPh, Donna Fausak, and Nicole Grassano have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians' Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurse Practitioners
Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121
This activity is accredited for 2.00 contact hour(s) which includes 0.00 hour(s) of pharmacology.
Activity ID #2304E
This activity was planned in accordance with AANP CE Standards and Policies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PER do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.